Publications
2020
28/10/2020
The New and the Old: Platform Cross-Validation of Immunoaffinity MASS Spectrometry versus ELISA for PromarkerD, a Predictive Test for Diabetic Kidney Disease
20/10/2020
A robust multiplex immunoafnity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease
09/10/2020
From Nanoflow to Standard Flow LC/MS for Routine Quantitative Plasma Proteomics in Diabetic Kidney Disease Research
06/10/2020
PromarkerD Predicts Renal Function Decline in Type 2 Diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
Newsroom
Private: In the Media
Presentations
Newsletters
Publications
Events
Categories
Biomarker Discovery
Drug Discovery
iTRAQ
Method Development
Patents
Proteogenomics
Proteomics
1
2
3
4
5
6
7
8
9
Subscribe
Title
Name
*
Position
Company/Organisation
*
Phone
Email
*
Terms & Conditions
*
I accept the terms and conditions
Name
This field is for validation purposes and should be left unchanged.
Company
About Us
Board
Clinical Advisory Board
Mission Statement
Senior Staff
Quality
Customer Testimonials
Careers
Glossary
PromarkerD
Diagnostics
Biomarker Discovery
The Promarkerâ„¢ Pipeline
Analytical Services
Pharmacokinetic Testing
Biosimilars/Biologics Drug Characterisation
Proteome Mapping
Proteome Quantitation (iTRAQ, TMT, Label-Free)
Targeted Mass Spectrometry (MRM/SRM)
Protein ID by Mass Spectrometry
Post-translational Modifications (PTMs)
Additional Services
Project Consultation
Pricing and Ordering
Terms and Conditions
FAQs
Newsroom
Media Releases
Media Coverage
Videos
Science & Technology
Presentations
Newsletters
Publications
Events
Investors
Share Price and Analyst Coverage
ASX Announcements
Corporate Media
Corporate Presentations
Library
Reports
Corporate Governance
Shareholder Information
Annual General Meeting
Contact
Sample Delivery
Technical
Business Development
Agents